Eleven Biotherapeutics, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics for ocular diseases, announced today the presentation of data for EBI-005, the first IL-1 (Interleukin-1) signaling inh…
Uncategorized
Healio.com wins 2012 Best Publishing Site award
Healio.com has been named winner of the 2012 Sitecore North American Site of the Year in the “Best Publishing Site” category. Sitecore is a global software company and the content management system (CMS) behind Healio.com. The Wyanoke Group worked with Sitecore partner Arke Systems to launch Healio.com in April 2012. In their commendation, Sitecore noted, “With the launch of Healio, Arke extended the Sitecore platform to new limits…The Healio site project has created a compelling story for the value associated with a content management system and customer relations management (CRM) (Read more...)
Rapid-Fire Advances in Cataract and Refractive Surgery
At X-rounds, speakers have only 3 minutes to present their ideas on how to improve cataract and refractive surgery, before the buzzer sounds. Medscape Ophthalmology
Massachusetts hospital performs first cornea transplant with pre-loaded donor tissue
The first successful cornea transplant with donor endothelial tissue preloaded by an eye bank has been performed at Massachusetts Eye and Ear in Boston, Mass. Roberto Pineda II, M.D., Director of the Refractive Surgery Service at Mass. Eye and Ear, and…
Use of a Comprehensive Polymerase Chain Reaction System for Diagnosis of Ocular Infectious Diseases – Corrected Proof
Purpose:
To measure the genomic DNA of ocular infectious pathogens in ocular fluids and to analyze the clinical relevance of these pathogens in uveitis and endophthalmitis.
Design:
Prospective clinical case series.
Participants:
A total of 500 pa…
Uncategorized
BCVA primary outcome maintained at 2 years in IVAN trial
SEATTLE — Gains in best corrected visual acuity that were achieved after the first three monthly injections of either ranibizumab or bevacizumab were maintained at 24 months in the IVAN trial, according to investigators presenting the data here. BCVA was the primary outcome of the 2-year trial.“Ranibizumab and bevacizumab have similar effects. What differences there are, are small,” Simon Harding, MD, FRCOphth, one of the investigators for the alternative treatments to inhibit VEGF in age-related choroidal neovascularization (IVAN) trial, said at the Association for Research in Vision and Ophthalmology meeting.